Semarion Ltd, a University of Cambridge spin-out company combining materials engineering and cell biology to tackle unmet drug screening needs, has just closed a £2.14m (US$2.89m) seed funding round.
New research findings suggest that an immunotherapy assay enables determination of PD-L1 status in a high percentage of cancer patients and could guide personalized treatment selection.
MiraiBio has released software for the statistical analysis of
multiplexed data generated on its liquid array detection system, a
platform that is designed for immunoassay, enzyme function, and
receptor-ligand interaction applications,...